Cargando…

Intracranial complete response for non‐small‐cell lung cancer patient with negative PD‐L1 expression of the lung using nivolumab

BACKGROUND: Nivolumab has shown promising results against non‐small‐cell lung cancer (NSCLC). However, its efficacy to treat central nervous system (CNS) metastases, specifically among programmed cell death 1 ligand 1 (PD‐L1)‐negative patients, remains unclear. CASE: A 66‐year‐old woman was diagnose...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kitadai, Rui, Zenke, Yoshitaka, Hishima, Tsunekazu, Hosomi, Yukio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8842707/ https://www.ncbi.nlm.nih.gov/pubmed/34042323 http://dx.doi.org/10.1002/cnr2.1460

Ejemplares similares

Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: Case series and literature review
por: Kitagawa, Shingo, et al.
Publicado: (2020)

Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation
por: Takagi, Yusuke, et al.
Publicado: (2013)

Intracranial Response to Nivolumab in a Patient with PD-L1-negative Lung Adenocarcinoma
por: Nakahara, Yoshiro, et al.
Publicado: (2018)

Successful Treatment of ALK-Positive Large-Cell Neuroendocrine Carcinoma of the Lung With Sequential ALK Inhibitors: A Case Report
por: Kobayashi, Takayuki, et al.
Publicado: (2023)

Malignant mesothelioma of the pleura with desmoplastic histology: a case series and literature review
por: Hashimoto, Kana, et al.
Publicado: (2016)

Crucial role of treatment with palliative intent for a patient with advanced thymic carcinoma
por: NAGAMATA, MAKOTO, et al.
Publicado: (2014)

Osseous oligometastases from thymic carcinoma: a case report suggesting the effectiveness of palliative-intent radiotherapy treatment
por: Kashima, Jumpei, et al.
Publicado: (2016)

A case of diffuse pulmonary ossification
por: Yomota, Makiko, et al.
Publicado: (2021)

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
por: Nomizo, Takashi, et al.
Publicado: (2017)

Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy
por: Uehara, Yuji, et al.
Publicado: (2022)

Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2016)

Erratum to: Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
por: Okuma, Yusuke, et al.
Publicado: (2016)

Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
por: Nicolazzo, Chiara, et al.
Publicado: (2016)

Observational study to predict the efficacy and optimal duration of nivolumab treatment in patients with previously treated advanced or recurrent non-small cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2022)

Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated Analysis
por: Fukuda, Akito, et al.
Publicado: (2022)

Pulmonary metastasis of matrix-producing carcinoma mimicking small cell lung cancer
por: Nakamura, Azusa, et al.
Publicado: (2022)

Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab
por: Ikeda, Mio, et al.
Publicado: (2021)

Nivolumab after Induction Chemotherapy in Previously Treated Non-Small-Cell Lung Cancer Patients with Low PD-L1 Expression
por: Ahn, Beung-Chul, et al.
Publicado: (2023)

Clinicopathological Factors Related to Recurrence Patterns of Resected Non-Small Cell Lung Cancer
por: Shimizu, Reiko, et al.
Publicado: (2020)

Nivolumab in Metastatic Non–Small Cell Lung Cancer
por: Deel, Andrea
Publicado: (2016)

Solitary glandular papilloma of the peripheral lung: a report of two cases
por: Kaseda, Kaoru, et al.
Publicado: (2014)

Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report
por: Naito, Tomoyuki, et al.
Publicado: (2019)

Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non–small Cell Lung Cancer
por: Inoue, Yusuke, et al.
Publicado: (2020)

Dramatic Response of Leptomeningeal Carcinomatosis to Nivolumab in PD-L1 Highly Expressive Non-small Cell Lung Cancer: A Case Report
por: Arias Ron, David, et al.
Publicado: (2019)

A Long-term Response to Nivolumab in a Case of PD-L1-negative Lung Adenocarcinoma with an EGFR Mutation and Surrounding PD-L1-positive Tumor-associated Macrophages
por: Watanabe, Hiromi, et al.
Publicado: (2019)

Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center
por: Okuma, Yusuke, et al.
Publicado: (2014)

A patient previously treated with ALK inhibitors for central nervous system lesions from ALK rearranged lung cancer: a case report
por: Kashima, Jumpei, et al.
Publicado: (2016)

Genetic and immunohistochemical analyses of ciliated muconodular papillary tumors of the lung: A report of five cases
por: Kashima, Jumpei, et al.
Publicado: (2019)

Nivolumab plus ipilimumab versus pembrolizumab as chemotherapy‐free, first‐line treatment for PD‐L1‐positive non‐small cell lung cancer
por: Zhou, Yixin, et al.
Publicado: (2020)

Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status
por: Katsura, Hideyuki, et al.
Publicado: (2019)

Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin
por: Watanabe, Kageaki, et al.
Publicado: (2020)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
por: Geier, Margaux, et al.
Publicado: (2020)

Efficacy and safety of nivolumab in non‐small cell lung cancer with preexisting interstitial lung disease
por: Kanai, Osamu, et al.
Publicado: (2018)

How long is cessation of preoperative smoking required to improve postoperative survival of patients with pathological stage I non-small cell lung cancer?
por: Shima, Toshiyuki, et al.
Publicado: (2020)

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
por: Rounis, Konstantinos, et al.
Publicado: (2021)

Extraosseous Benign Notochordal Cell Tumor Originating in the Lung: A Case Report
por: Takahashi, Yusuke, et al.
Publicado: (2015)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Factors Associated With Efficacy and Nivolumab-Related Interstitial Pneumonia in Non-Small Cell Lung Cancer: A Retrospective Survey
por: Hata, Hiroki, et al.
Publicado: (2020)

Treatment Strategies for Non-Small Cell Lung Cancer Harboring Common and Uncommon EGFR Mutations: Drug Sensitivity Based on Exon Classification, and Structure-Function Analysis
por: Kitadai, Rui, et al.
Publicado: (2022)

PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
por: Larsen, Trine Vilsbøll, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nf2vhfjreeuqeofhq0mte5ajtu